Andere talen Cyclerion Therapeutics, Inc.

Aandelen

CYCN

US23255M2044

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,77 ^USD	-9,18%		-13,93%	-17,31%

05/03	Cyclerion Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	Cyclerion Therapeutics, Inc. Benoemt Regina Graul tot President	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Cyclerion Appoints Regina Graul, Ph.D., as President	04/12
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	04/12
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	01/12
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	01/12
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	24/11
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23-10-23
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	01-08-23
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31-07-23
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	31-07-23
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	31-07-23
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28-07-23
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	27-06-23
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01-06-23
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	01-06-23
Cyclerion Therapeutics : Private Placement - Form 8-K	25-05-23
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	25-05-23
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	25-05-23
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	15-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cyclerion Therapeutics, Inc.

Aandelen

CYCN

US23255M2044

Andere talen

Filters